

2019 Influenza A Virus H5N1 Subtype Infections R&D Pipeline Drugs, Companies, Trials and Developments

https://marketpublishers.com/r/2C48C30A817EN.html

Date: March 2019

Pages: 130

Price: US\$ 2,199.00 (Single User License)

ID: 2C48C30A817EN

Abstracts

The global demand for Influenza A Virus H5N1 Subtype Infections treatment options is expected to report strong growth over the medium to long term future driven by consumption in major markets. Strong growth prospects of drugs for Influenza A Virus H5N1 Subtype Infections are driving leading companies to invest their resources on the pipeline.

Companies quickly advancing their drug candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Influenza A Virus H5N1 Subtype Infections pipeline companies from advancing their products.

Influenza A Virus H5N1 Subtype Infections Report Description

The H1-2019 pipeline review report on Influenza A Virus H5N1 Subtype Infections is a comprehensive study on drug candidates across different phases worldwide. This report evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date.

The Influenza A Virus H5N1 Subtype Infections pipeline guide presents information on all active drugs currently being developed for Influenza A Virus H5N1 Subtype Infections. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Influenza A Virus H5N1 Subtype Infections pipeline candidate are analyzed.

Further, current phase of development, mechanism of action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all



Influenza A Virus H5N1 Subtype Infections drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Influenza A Virus H5N1 Subtype Infections product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Influenza A Virus H5N1 Subtype Infections pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

The publisher has developed the report based on robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Influenza A Virus H5N1 Subtype Infections pipeline report includes-

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise pipeline compounds

Company wise list of pipeline compounds

Mechanism of Action wise pipeline compounds

For each pipeline product, the following details are provided-

Snapshot (Drug, , Phase, Co Developer, Originator, Synonym, Orphan Drug Status, Type of Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action



Pre-clinical and Clinical Trials

REASONS TO BUY

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Influenza A Virus H5N1 Subtype Infections pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Influenza A Virus H5N1 Subtype Infections pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into the market through in-depth strategic analysis review

Know the list of companies participating in global Influenza A Virus H5N1 Subtype Infections pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.



Contents

GLOBAL INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS PIPELINE OVERVIEW

Key Findings, 2019
Disease Overview
Report Guide and Research Methodology

EXECUTIVE SUMMARY

Influenza A Virus H5N1 Subtype Infections Drugs under active development, H1@2019 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)

Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)

Companies involved in Influenza A Virus H5N1 Subtype Infections pipeline, H1@2019

Mechanism of Action wise Influenza A Virus H5N1 Subtype Infections Pipeline

Candidates

ABIVAX SA INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS PIPELINE DETAILS

Business Profile

Drug Details

Drug Snapshot

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

ABZYME THERAPEUTICS LLC INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS PIPELINE DETAILS



Business Profile

Drug Details

Drug Snapshot

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

AKSHAYA BIO INC INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS PIPELINE DETAILS

Business Profile

Drug Details

Drug Snapshot

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

ALPHAVAX INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS PIPELINE DETAILS

Business Profile

Drug Details



Drug Snapshot

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

ALTIMMUNE INC INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS PIPELINE DETAILS

Business Profile

Drug Details

Drug Snapshot

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

ANTIGEN EXPRESS INC INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS PIPELINE DETAILS

Business Profile

Drug Details

Drug Snapshot

Originator

Collaborator/Co-Developer



Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

APHIOS CORP INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS PIPELINE DETAILS

Business Profile

Drug Details

Drug Snapshot

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

AUSBIO LTD INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS PIPELINE DETAILS

Business Profile

Drug Details

Drug Snapshot

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area



Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

BIONDVAX PHARMACEUTICALS LTD INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS PIPELINE DETAILS

Business Profile

Drug Details

Drug Snapshot

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

CAPTIVATE PHARMACEUTICALS LLC INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS PIPELINE DETAILS

Business Profile

Drug Details

Drug Snapshot

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

Current Status

Drug Overview



Drug Mechanism of Action Clinical/Pre-clinical Trial Details Latest Drug Developments

CEL-SCI CORP INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS PIPELINE DETAILS

Business Profile

Drug Details

Drug Snapshot

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

CHICAGO BIOSOLUTIONS INC INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS PIPELINE DETAILS

Business Profile

Drug Details

Drug Snapshot

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments



CHO PHARMA INC INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS PIPELINE DETAILS

Business Profile

Drug Details

Drug Snapshot

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

COCRYSTAL PHARMA INC INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS PIPELINE DETAILS

Business Profile

Drug Details

Drug Snapshot

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

CUREVAC AG INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS PIPELINE DETAILS



Business Profile

Drug Details

Drug Snapshot

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

DECLION PHARMACEUTICALS INC INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS PIPELINE DETAILS

Business Profile

Drug Details

Drug Snapshot

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

FIDES PHARMA SPA INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS PIPELINE DETAILS

Business Profile

Drug Details



Drug Snapshot

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

FORGE LIFE SCIENCE LLC INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS PIPELINE DETAILS

Business Profile

Drug Details

Drug Snapshot

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

GAMMA VACCINES PTY LTD INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS PIPELINE DETAILS

Business Profile

Drug Details

Drug Snapshot

Originator

Collaborator/Co-Developer



Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

GREFFEX INC INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS PIPELINE DETAILS

Business Profile

Drug Details

Drug Snapshot

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

HEMISPHERX BIOPHARMA INC INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS PIPELINE DETAILS

Business Profile

Drug Details

Drug Snapshot

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area



Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

IBIO INC INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS PIPELINE DETAILS

Business Profile

Drug Details

Drug Snapshot

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

INOVIO PHARMACEUTICALS INC INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS PIPELINE DETAILS

Business Profile

Drug Details

Drug Snapshot

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action



Clinical/Pre-clinical Trial Details Latest Drug Developments

KINETA INC INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS PIPELINE DETAILS

Business Profile

Drug Details

Drug Snapshot

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

MEDICAGO INC INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS PIPELINE DETAILS

Business Profile

Drug Details

Drug Snapshot

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments



MEDIGEN INC INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS PIPELINE DETAILS

Business Profile

Drug Details

Drug Snapshot

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

NANOVIRICIDES INC INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS PIPELINE DETAILS

Business Profile

Drug Details

Drug Snapshot

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

OPKO HEALTH INC INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS PIPELINE DETAILS



Business Profile

Drug Details

Drug Snapshot

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

PEPTIDREAM INC INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS PIPELINE DETAILS

Business Profile

Drug Details

Drug Snapshot

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

SEQIRUS LTD INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS PIPELINE DETAILS

Business Profile

Drug Details

Drug Snapshot



Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

SHIONOGI & CO LTD INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS PIPELINE DETAILS

Business Profile

Drug Details

Drug Snapshot

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

VACTHERA BIOTECH GMBH INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS PIPELINE DETAILS

Business Profile

Drug Details

Drug Snapshot

Originator

Collaborator/Co-Developer

Route of Administration



Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

VAXART INC INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS PIPELINE DETAILS

Business Profile

Drug Details

Drug Snapshot

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

VAXINE PTY LTD INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS PIPELINE DETAILS

Business Profile

Drug Details

Drug Snapshot

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity



Current Status

Drug Overview

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

VERTEX PHARMACEUTICALS INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS PIPELINE DETAILS

Business Profile

Drug Details

Drug Snapshot

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

VIRVIO INC INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS PIPELINE DETAILS

Business Profile

Drug Details

Drug Snapshot

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action



Clinical/Pre-clinical Trial Details Latest Drug Developments

LATEST INFLUENZA A VIRUS H5N1 SUBTYPE INFECTIONS DRUG PIPELINE DEVELOPMENTS, 2019

APPENDIX

About Us Sources and Methodology Contact Information



I would like to order

Product name: 2019 Influenza A Virus H5N1 Subtype Infections R&D Pipeline Drugs, Companies, Trials

and Developments

Product link: https://marketpublishers.com/r/2C48C30A817EN.html

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/2C48C30A817EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

